Geron Announces Data Presentations From IMerge Phase 3 Evaluating Imetelstat In Lower Risk MDS At Society Of Hematologic Oncology Annual Meeting
Portfolio Pulse from Happy Mohamed
Geron Corporation (NASDAQ:GERN) has announced data presentations from its Phase 3 clinical trial, IMerge, evaluating its investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The data, presented at the Society of Hematologic Oncology Annual Meeting, showed promising results including transfusion independence, increases in hemoglobin, and improvement in fatigue. Based on these results, Geron has submitted a New Drug Application for imetelstat that has been accepted for review by the FDA.
September 07, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron's Phase 3 trial data for imetelstat shows promising results, leading to a New Drug Application submission. This could potentially lead to a new revenue stream if the drug is approved by the FDA.
The positive results from the Phase 3 trial of imetelstat and the subsequent submission of a New Drug Application to the FDA are significant for Geron. If the drug is approved, it could open up a new revenue stream for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100